BioLineRx (BLRX)
(Delayed Data from NSDQ)
$0.46 USD
-0.05 (-8.91%)
Updated Oct 4, 2024 03:59 PM ET
After-Market: $0.45 -0.01 (-2.17%) 7:28 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for BioLineRx Ltd falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 43 | 51 | 57 | 23 | 27 |
Receivables | 1 | 1 | 0 | 0 | 1 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 2 | 0 | 0 | 0 | 0 |
Other Current Assets | 1 | 0 | 0 | 0 | 0 |
Total Current Assets | 47 | 52 | 57 | 23 | 28 |
Net Property & Equipment | 0 | 1 | 1 | 1 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 15 | 22 | 22 | 22 | 22 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 64 | 76 | 81 | 47 | 54 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 14 | 9 | 7 | 7 | 9 |
Current Portion Long-Term Debt | 3 | 2 | 3 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 13 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 31 | 11 | 10 | 11 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 7 | 9 | 0 | 3 | 6 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 12 | 5 | 2 | 10 | 1 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 51 | 26 | 13 | 25 | 20 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 31 | 27 | 21 | 10 | 5 |
Capital Surplus | 372 | 354 | 353 | 292 | 278 |
Retained Earnings | -391 | -330 | -305 | -278 | -248 |
Other Equity | 0 | 0 | 0 | -1 | -1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 13 | 51 | 68 | 22 | 33 |
Total Liabilities & Shareholder's Equity | 64 | 76 | 81 | 47 | 54 |
Total Common Equity | 13 | 51 | 68 | 22 | 33 |
Shares Outstanding | 72.40 | 61.50 | 47.60 | 32.20 | 7.40 |
Book Value Per Share | 0.18 | 0.83 | 1.43 | 0.68 | 4.51 |
Fiscal Year End for BioLineRx Ltd falls in the month of December.
All items in Millions except Per Share data.
9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 40 | 28 | 43 | 26 | 33 |
Receivables | 4 | 3 | 1 | 0 | 0 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 3 | 2 | 1 | 0 |
Other Current Assets | 2 | 1 | 1 | 1 | 2 |
Total Current Assets | 49 | 36 | 47 | 29 | 35 |
Net Property & Equipment | 0 | 0 | 0 | 1 | 1 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 14 | 14 | 15 | 22 | 22 |
Deposits & Other Assets | 0 | 0 | 0 | 0 | 0 |
Total Assets | 65 | 52 | 64 | 53 | 59 |
Liabilities & Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 9 | 11 | 14 | 11 | 9 |
Current Portion Long-Term Debt | 11 | 4 | 3 | 3 | 3 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 0 | 0 | 0 | 0 | 0 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 11 | 17 | 13 | 0 | 0 |
Total Current Liabilities | 31 | 31 | 31 | 15 | 12 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 19 | 6 | 7 | 8 | 9 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 12 | 15 | 15 | |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 51 | 39 | 51 | 40 | 38 |
Shareholders Equity | 9/30/2024 | 6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 34 | 31 | 31 | 28 | 27 |
Capital Surplus | 370 | 373 | 372 | 362 | 355 |
Retained Earnings | -391 | -391 | -391 | -377 | -361 |
Other Equity | 0 | 0 | 0 | 0 | 0 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 14 | 13 | 13 | 13 | 21 |
Total Liabilities & Shareholder's Equity | 65 | 52 | 64 | 53 | 59 |
Total Common Equity | 14 | 13 | 13 | 13 | 21 |
Shares Outstanding | 79.90 | 79.90 | 72.40 | 61.50 | 61.50 |
Book Value Per Share | 0.17 | 0.16 | 0.18 | 0.21 | 0.34 |